Reports Q1 revenue $52.44M, consensus $42.13M. “We had a strong start to 2025 with 34% MRD revenue growth, driven by continued acceleration in clonoSEQ test volume and disciplined execution,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies (ADPT). “This performance highlights the scalability of our MRD business and the growing momentum behind it. As a result, we are raising our full year MRD revenue guidance while lowering our operating expenses and cash burn targets. As we move forward, we remain focused on driving our MRD business to profitability and advancing our Immune Medicine drug discovery programs to deliver long-term value for all our stakeholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies: Promising Growth with Expanded Medicare Coverage and Strong Market Position
- Adaptive Biotechnologies receives expanded medical coverage of clonoSEQ
- Biotech Alert: Searches spiking for these stocks today
- Morning Movers: FedEx, Nike headline dip in corporate outlooks
- Adaptive Biotechnologies upgraded to Buy from Neutral at Goldman Sachs